Five Tips for Successful Commercialization of Lab-on-a-Chip Diagnostics
Conference Recording Feb 21, 2013
About the SpeakerOriginally trained in laser and plasma physics, Erol Harvey has been involved in commercial and academic development of micro, nano and bio production techniques for more than 20 years. A former Professor of Microtechnology at Swinburne University, he is a founder and CEO of MiniFAB, a product development company and OEM volume manufacturer of polymer based microfluidic, lab-on-a-chip diagnostic devices for clients around the world. In 2012 he was inducted into the Victorian Manufacturing Hall of Fame for entrepreneurship in emerging technologies and is a volunteer business mentor within the government’s Commercialisation Australia program.
Successful technology transfer from laboratory prototype to full-scale manufacture of medical diagnostic products is about managing complexity. While there are many promising emerging technologies in this field, there are a multitude of development hurdles facing each product development effort, including manufacturability, scale-up, and regulatory issues. Solutions rely on a combination of factors: development of enabling technologies for modular components; integration of key components into systems using novel, low cost manufacturing techniques; interfacing of systems to the external environment and most importantly, understanding the requirements of the user community and target markets. The rapidly growing field of lab-on-chip point-of-care devices is an area ripe with opportunities to accelerate product development. Robust understanding of these factors will enable successful translation and commercialization such as creating useful cost models to guide design, development and investment decisions. MiniFAB will share Five Tips for Successful Commercialization of Lab-on-Chip Diagnostics. Whether developing a novel microfluidic system or converting an existing assay into a new point of care product, this methodology is applicable for both large and small scale product development, as well as for large corporations, SMEs or research institutions.